E-Mail
A new study suggests that a hormone known to prevent weight gain and normalize metabolism can also help maintain healthy muscles in mice. The findings present new possibilities for treating muscle-wasting conditions associated with age, obesity or cancer, according to scientists from the University of Southern California Leonard Davis School of Gerontology.
The research, published this month in the
American Journal of Physiology-Endocrinology and Metabolism, addresses the related problems of age and obesity-induced muscle loss, conditions which can lead to increased risk of falls, diabetes and other negative health impacts. It also adds to a growing number of findings describing beneficial effects of MOTS-c, a mitochondrial-derived peptide that is known to mimic the effects of exercise.
High Court upholds not guilty verdict in OBI Pharma case
Staff writer, with CNA
The High Court yesterday upheld a not-guilty ruling in an insider trading case involving OBI Pharma chairman Michael Chang (張念慈) and four of the company’s executives.
The high court upheld the Shilin District Court’s ruling in June 2019 that there was insufficient evidence showing that Chang, general manager Amy Huang (黃秀美), former vice chairman Hsu Yo-gung (許友恭), research and development director Yu Cheng-te (游丞德) and administration division manager Liao Tsung-chih (廖宗智) committed insider trading.
The ruling can be appealed.
Taiwan High Court criminal division spokeswoman Liu Fang-tsu talks to the media about a ruling involving OBI Pharma Inc at a news conference in Taipei yesterday.
High court upholds ruling in OBI Pharma insider trading case
01/26/2021 03:44 PM
A Taiwan High Court spokesperson holds a press conference on the ruling. CNA photo Jan. 26, 2021
Taipei, Jan. 26 (CNA) The Taiwan High Court on Tuesday upheld a lower court s not-guilty ruling in an insider trading case involving OBI Pharma Chairman Michael Chang (張念慈) and four other company executives.
The high court upheld the Shilin District Court s ruling in June 2019 that there was insufficient evidence showing that Chang, general manager Amy Huang (黃秀美), former vice chair Hsu Yo-gung (許友恭), research and development director Yu Cheng-te (游丞德) and administration division manager Liao Tsung-chih (廖宗智) committed insider trading.
Bryte raises $24M and begins licensing its tech in addition to selling $8K AI-powered mattresses
Bryte today announced $24 million in Series A funding led by ARCHina Capital. This comes as the company moves away from selling its $8,000 mattress direct to consumers and instead is working with partners who will utilize Bryte’s technology in their mattresses.
Bryte says several deals are in the works.
According to the company, this pivot has always been part of the plan. They feel that through licensing, they can better accomplish the company’s goal of improving people’s sleep experience. Bryte doesn’t want to become another direct to consumer brand, but rather the underlying technology in some of the best mattresses.
The Restorative Bed consumer system powered by iPhone or Android mobile app
The Restorative Bed hospitality system with dedicated bedside tablets at The London West Hollywood at Beverly Hills. Photo Credit Tanveerbadal.com
Bryte, best known for creating the world s most advanced AI-connected and robotics-powered bed, has recently launched its platform to license their patented restorative sleep technology as a turn-key solution to accelerate widespread adoption across mattress manufacturers at scale. Bryte is now engaged with multiple global mattress manufacturers, and funding will go towards R&D and expansion across markets and price points. We believe that the Bryte platform will accelerate the restorative sleep tech revolution for the entire $432bn sleep industry, much as Luminar is accelerating autonomous driving adoption across automakers and Carbon is accelerating mass customization in the manufacturing industry, says Huang.